Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials

Backgrounds. Many clinical trials have demonstrated the value of drug-coated balloons (DCB) for in-stent restenosis. However, their role in de novo lesions is not well documented. The aim of this study is to evaluate the safety and efficacy of the DCB-only strategy compared to other percutaneous cor...

Full description

Bibliographic Details
Main Authors: Wenyi Zhang, Mingduo Zhang, Jinfan Tian, Min Zhang, Yuan Zhou, Xiantao Song
Format: Article
Language:English
Published: Hindawi-Wiley 2023-01-01
Series:Cardiovascular Therapeutics
Online Access:http://dx.doi.org/10.1155/2023/3121601
_version_ 1797742997893283840
author Wenyi Zhang
Mingduo Zhang
Jinfan Tian
Min Zhang
Yuan Zhou
Xiantao Song
author_facet Wenyi Zhang
Mingduo Zhang
Jinfan Tian
Min Zhang
Yuan Zhou
Xiantao Song
author_sort Wenyi Zhang
collection DOAJ
description Backgrounds. Many clinical trials have demonstrated the value of drug-coated balloons (DCB) for in-stent restenosis. However, their role in de novo lesions is not well documented. The aim of this study is to evaluate the safety and efficacy of the DCB-only strategy compared to other percutaneous coronary intervention strategies for de novo coronary lesions. Methods. The PubMed, Embase, Web of Science, and Cochrane Library Central Register of Controlled Trials (CENTRAL) electronic databases were searched for randomized controlled trials published up to May 6, 2023. The primary outcomes were major adverse cardiac events and late lumen loss. Results. A total of eighteen trials with 3336 participants were included. Compared with drug-eluting stents, the DCB-only strategy was associated with a similar risk of major adverse cardiac events (risk ratio RR=0.90; 95% confidence interval (CI): 0.59 to 1.37, P=0.631) and a significant decrease in late lumen loss (standardized mean difference SMD=−0.29, 95% CI: −0.53 to −0.04, P=0.021). This effect was consistent in subgroup analysis regardless of indication, follow-up time, drug-eluting stent type, and dual antiplatelet therapy duration. However, DCBs were inferior to DESs for minimum lumen diameter and percentage diameter stenosis. The DCB-only strategy showed significantly better outcomes for most endpoints compared to plain-old balloon angioplasty or bare metal stents. Conclusions. Interventions with a DCB-only strategy are comparable to those of drug-eluting stents and superior to plain-old balloon angioplasty or bare metal stents for the treatment of selected de novo coronary lesions. Additional evidence is still warranted to confirm the value of DCB before widespread clinical utilization can be recommended.
first_indexed 2024-03-12T14:48:15Z
format Article
id doaj.art-d4e34dbdd3794e64b793005c8b2558a8
institution Directory Open Access Journal
issn 1755-5922
language English
last_indexed 2024-03-12T14:48:15Z
publishDate 2023-01-01
publisher Hindawi-Wiley
record_format Article
series Cardiovascular Therapeutics
spelling doaj.art-d4e34dbdd3794e64b793005c8b2558a82023-08-16T00:00:01ZengHindawi-WileyCardiovascular Therapeutics1755-59222023-01-01202310.1155/2023/3121601Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical TrialsWenyi Zhang0Mingduo Zhang1Jinfan Tian2Min Zhang3Yuan Zhou4Xiantao Song5Department of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyBackgrounds. Many clinical trials have demonstrated the value of drug-coated balloons (DCB) for in-stent restenosis. However, their role in de novo lesions is not well documented. The aim of this study is to evaluate the safety and efficacy of the DCB-only strategy compared to other percutaneous coronary intervention strategies for de novo coronary lesions. Methods. The PubMed, Embase, Web of Science, and Cochrane Library Central Register of Controlled Trials (CENTRAL) electronic databases were searched for randomized controlled trials published up to May 6, 2023. The primary outcomes were major adverse cardiac events and late lumen loss. Results. A total of eighteen trials with 3336 participants were included. Compared with drug-eluting stents, the DCB-only strategy was associated with a similar risk of major adverse cardiac events (risk ratio RR=0.90; 95% confidence interval (CI): 0.59 to 1.37, P=0.631) and a significant decrease in late lumen loss (standardized mean difference SMD=−0.29, 95% CI: −0.53 to −0.04, P=0.021). This effect was consistent in subgroup analysis regardless of indication, follow-up time, drug-eluting stent type, and dual antiplatelet therapy duration. However, DCBs were inferior to DESs for minimum lumen diameter and percentage diameter stenosis. The DCB-only strategy showed significantly better outcomes for most endpoints compared to plain-old balloon angioplasty or bare metal stents. Conclusions. Interventions with a DCB-only strategy are comparable to those of drug-eluting stents and superior to plain-old balloon angioplasty or bare metal stents for the treatment of selected de novo coronary lesions. Additional evidence is still warranted to confirm the value of DCB before widespread clinical utilization can be recommended.http://dx.doi.org/10.1155/2023/3121601
spellingShingle Wenyi Zhang
Mingduo Zhang
Jinfan Tian
Min Zhang
Yuan Zhou
Xiantao Song
Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials
Cardiovascular Therapeutics
title Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials
title_full Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials
title_fullStr Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials
title_full_unstemmed Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials
title_short Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials
title_sort drug coated balloon only strategy for de novo coronary artery disease a meta analysis of randomized clinical trials
url http://dx.doi.org/10.1155/2023/3121601
work_keys_str_mv AT wenyizhang drugcoatedballoononlystrategyfordenovocoronaryarterydiseaseametaanalysisofrandomizedclinicaltrials
AT mingduozhang drugcoatedballoononlystrategyfordenovocoronaryarterydiseaseametaanalysisofrandomizedclinicaltrials
AT jinfantian drugcoatedballoononlystrategyfordenovocoronaryarterydiseaseametaanalysisofrandomizedclinicaltrials
AT minzhang drugcoatedballoononlystrategyfordenovocoronaryarterydiseaseametaanalysisofrandomizedclinicaltrials
AT yuanzhou drugcoatedballoononlystrategyfordenovocoronaryarterydiseaseametaanalysisofrandomizedclinicaltrials
AT xiantaosong drugcoatedballoononlystrategyfordenovocoronaryarterydiseaseametaanalysisofrandomizedclinicaltrials